{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:20:40Z","timestamp":1792790440971,"version":"4.5.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The optimal treatment strategy for advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remains undefined. Although combinations of locoregional therapies\u2014such as transarterial chemoembolization (TACE) and hepatic arterial infusion chemotherapy (HAIC)\u2014with systemic agents (tyrosine kinase inhibitors [TKIs] and PD-1 inhibitors) show promise, direct comparative evidence among different regimens remains limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this single-center retrospective study, we included 347 patients with unresectable HCC and PVTT treated between January 2020 and December 2022. Patients were categorized into four groups based on initial therapy: TACE-HAIC-TP (n = 79), TACE-TP (n = 90), HAIC-TP (n = 98), and TACE alone (n = 80). The primary endpoints were overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All combination regimens significantly improved OS and PFS compared with TACE alone (median OS: 11.4 months; median PFS: 5.8 months; all p &amp;lt; 0.001). The TACE-HAIC-TP group had the longest median OS (21.0 months) and PFS (15.3 months). However, after propensity score matching, no significant difference in survival outcomes was observed between the TACE-HAIC-TP and HAIC-TP groups. The HAIC-TP and TACE-TP regimens demonstrated comparable efficacy. Regarding safety, TACE-HAIC-TP was associated with the highest incidence of adverse events, including appetite loss, fatigue, nausea\/vomiting, bleeding, and immune-related pneumonia. HAIC-TP carried a higher risk of gastrointestinal reactions and bleeding, whereas hand-foot syndrome was more frequent with TACE-TP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with unresectable HCC and PVTT, combining TKIs and PD-1 inhibitors with locoregional therapy (TACE or HAIC) confers superior survival benefits over TACE monotherapy. The HAIC-TP regimen was associated with a more favorable balance of efficacy and tolerability compared with the more intensive TACE-HAIC-TP strategy, suggesting it may represent a promising therapeutic option pending prospective validation. Treatment selection should be individualized based on efficacy\u2013safety trade-offs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1776852","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:29:03Z","timestamp":1773120543000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of locoregional and systemic therapy for hepatocellular carcinoma with portal vein tumor thrombus: a real-world retrospective study"],"prefix":"10.3389","volume":"16","author":[{"given":"Xunbo","family":"Hou","sequence":"first","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Yin","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RuiBao","family":"Liu","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiannan","family":"Xu","sequence":"additional","affiliation":[{"name":"Fourth Affiliated Hospital of Harbin Medical University","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingchen","family":"Li","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bowen","family":"Liu","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Liu","sequence":"additional","affiliation":[{"name":"Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jhep.2022.10.006","article-title":"Corrigendum to \u2018EASL recommendations on treatment of hepatitis C: Final update of the series","volume":"78","year":"2023","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2217\/hep-2018-0002","article-title":"Hepatocellular carcinoma treatment: hurdles, advances and prospects","volume":"5","author":"Kumari","year":"2018","journal-title":"Hepat Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1159\/000546574","article-title":"China liver cancer guidelines for the diagnosis and treatment of hepatocellular carcinoma (2024 edition)","volume":"14","author":"Zhou","year":"2025","journal-title":"Liver Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31424","article-title":"Local and regional therapies for hepatocellular carcinoma","volume":"73","author":"Kloeckner","year":"2021","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2022.7989","article-title":"Management of hepatocellular carcinoma: A review","volume":"158","author":"Brown","year":"2023","journal-title":"JAMA Surg"},{"key":"B6","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ijsu.2015.05.009","article-title":"The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus","volume":"20","author":"Zhang","year":"2015","journal-title":"Int J Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","article-title":"Cancer treatments: Past, present, and future","author":"Sonkin","year":"2024","journal-title":"Cancer Genet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.jvir.2017.04.025","article-title":"Quality improvement guidelines for transarterial chemoembolization and embolization of hepatic Malignancy","volume":"28","author":"Gaba","year":"2017","journal-title":"J Vasc Interv Radiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30010096","article-title":"Efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors for hepatocellular carcinoma patients with portal vein tumor thrombus: A systematic review and meta-analysis","volume":"30","author":"Deng","year":"2023","journal-title":"Curr Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102622","article-title":"Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study","volume":"72","author":"Jin","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)02551-0","article-title":"Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study","volume":"405","author":"Sangro","year":"2025","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2147\/jhc.S537950","article-title":"TACE-HAIC versus TACE as Initial Regional Therapy for Unresectable Huge Hepatocellular Carcinoma (>10 cm): A Propensity Score-Matched Study","volume":"12","author":"Liu","year":"2025","journal-title":"J Hepatocell Carcinoma"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e057","DOI":"10.1097\/as9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg Open"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2024.02.06","article-title":"New insights into mechanisms and interventions of locoregional therapies for hepatocellular carcinoma","volume":"36","author":"Liu","year":"2024","journal-title":"Chin J Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3892\/ol.2025.15078","article-title":"Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review)","volume":"30","author":"Xu","year":"2025","journal-title":"Oncol Lett"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01720-9","article-title":"Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2\/3 trial","volume":"406","author":"Wang","year":"2025","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/s41467-025-56537-y","article-title":"The anti-PD-L1\/CTLA-4 bispecific antibody KN046 plus lenvatinib in advanced unresectable or metastatic hepatocellular carcinoma: a phase II trial","volume":"16","author":"Xu","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.848387","article-title":"Transarterial chemoembolization combined with lenvatinib plus PD-1 inhibitor for advanced hepatocellular carcinoma: A retrospective cohort study","volume":"13","author":"Cai","year":"2022","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e7105","DOI":"10.1002\/cam4.7105","article-title":"Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma","volume":"13","author":"Fu","year":"2024","journal-title":"Cancer Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cancergen.2025.03.004","article-title":"Identification of new immune target and signaling for cancer immunotherapy","author":"Narote","year":"2025","journal-title":"Cancer Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-03031-9","article-title":"Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment","volume":"45","author":"Llovet","year":"2022","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669856","article-title":"TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1776852\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:29:06Z","timestamp":1773120546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1776852\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":24,"alternative-id":["10.3389\/fonc.2026.1776852"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1776852","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"article-number":"1776852"}}